Emerging Market for Clinical Trials in Argentina - Major Cost Advantages over the US in Conducting Clinical Trials Will Encourage Drug Development Rising Financial and Regulatory Pressures on Western Pharma Will Continue to Drive the Clinical Trial Market Growth in Argentina The pharmaceutical industries of the US and Europe have been facing severe financial constraints over the past few years, and these are expected to worsen in the coming years. With constraints such as the cost of introducing an NME increasing to reach more than $3 billion in 2008, tightening regulatory pressures resulting in fewer FDA approvals, blockbuster drugs worth more than $100 billion set to expire by 2014 and the drying pipelines of the pharmaceutical industry, pressures are mounting on pharmaceutical companies to cut costs, especially the big ones. These pressures are expected to drive these companies towards low-cost countries such as Argentina to perform their R&D activities, one of their major expenses. Argentina has developed significant capabilities in clinical trials over the last decade, along with certain capabilities especially for diabetes indication. Argentina is able to provide significant cost savings in the range of 50–60% for clinical trials. With discovery research occupying close to onethird of the R&D expenditure for the western pharmaceutical industry, outsourcing to low-cost countries is logical. For Sample Pages, please click or add the below link to your browser: http://www.gbiresearch.com/RequestSamplePages.aspx?ID=Emerging-Market-for-Clinical-Trials-inArgentina-Major-Cost-Advantages-over-the-US-in-Conducting-Clinical-Trials-Will-Encourage-DrugDevelopment&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report The figure above depicts the population of Argentina according to age groups from 1980 to 2050. As evident from the figure, Argentina’s population will experience a dramatic shift in its age structure. In 2030 its total population is expected to be above 50 million, with 14.5 million of its people above the age of 50. In 2050, it is estimated that this number will rise to nearly 19.5 million. This means that there will be a rise in chronic diseases, which generally affect this population age group. GBI Research, the leading business intelligence provider, has released its latest report, “Emerging Market for Clinical Trials in Argentina - Major Cost Advantages over the US in Conducting Clinical Trials Will Encourage Drug Development”, which provides key data, information and analysis of the major trends and issues affecting the clinical trial market in Argentina. The report provides a comprehensive insight into the reasons for outsourcing clinical trials to Argentina and the key services provided by the CROs of Argentina. The report provides a detailed analysis of the Argentine market in terms of its size and the major service offerings of the CROs in Argentina. The report also discusses the factors that are driving the clinical trial market in Argentina. The report delves into the key documents required by the investigator and the sponsor before, during and after
the conduct of clinical trials. The report also provides key alliances between the CROs of other countries and the local CROs of Argentina. The report also looks into the major challenges that could restrict the growth of the clinical trials market in Argentina. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. For further details, please click or add the below link to your browser: http://www.gbiresearch.com/Report.aspx?ID=Emerging-Market-for-Clinical-Trials-in-Argentina-MajorCost-Advantages-over-the-US-in-Conducting-Clinical-Trials-Will-Encourage-DrugDevelopment&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report Visit our report store: http://www.gbiresearch.com For more details contact: pressreleases@gbiresearch.com North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782